FDA approves Novavax's Nuvaxovid 2025-2026 formula for prevention of COVID-19
Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season
Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season
Merger is expected to streamline operations and provide unified management focus, driving efficiency and strategic alignment
AiMeD noted that proposed GST changes—to either 5% or 18%—both present significant risks requiring carefully nuanced consideration
Guidelines aim to establish state-regulated veterinary blood banks
The complex four-hour surgery was performed by a multidisciplinary team of doctors
Anthony brings more than 25 years of pharmaceutical development and CRO experience to his expanded role
The ‘265 Patent is based on Enanta’s July 2020 patent application describing coronavirus protease inhibitors invented by Enanta scientists
Subscribe To Our Newsletter & Stay Updated